Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
NF2
PD-L1
comprehensive genomic profiling
genomic alteration
kidney tumors
renal cell carcinoma
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
06
11
2022
accepted:
27
01
2023
medline:
7
7
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
Genomic alterations (GA) in NF2 tumor-suppressor gene have been associated with aggressive behavior in kidney tumors. We used comprehensive genomic profiling (CGP) to evaluate the frequencies of NF2 GA in histologic subtypes of kidney tumors and co-occurring GA in other genes and biomarkers. Advanced kidney tumors included 1875 clear cell (ccRCC), 405 papillary (pRCC), 108 chromophobe (chRCC), 171 sarcomatoid (sRCC), 61 collecting duct (cdRCC), 49 medullary (mRCC), 134 unclassified (uRCC), 906 urothelial carcinoma of renal pelvis (UC), and 147 Wilms tumors underwent hybrid-capture based CGP to evaluate all classes of GA. 192 (4.9%) of kidney tumors featured NF2 GA which were predominantly structural variant mutations (89%), followed by copy number alterations (9%). Gender and age were similar between NF2-mutant (NF2mut) and NF2-wild type (NF2wt) cohorts with male preponderance. NF2 GA frequency was highest in cdRCC (30%), sRCC (21%), uRCC (15%), and pRCC (12%) while lowest in ccRCC (3%), UC (3%) Wilms tumor (1%), and chRCC (0%). NF2 mutational status was associated with loss of Ch 22 (P < .001). NF2mut RCC harbored co-occurring GA including CDKN2A, CDKN2B, SETD2, and BAP1. VHL, PBRM1, PTEN, and FGFR3 GA were significantly more frequent in NF2wt than in NF2mut tumors. MTOR pathway GAs were uncommon in NF2mut tumors. No NF2 mutated RCC featured MSI-high or high TMB. sRCC was associated with high PD-L1 expression. PD-L1 SP142 tumoral (P = .04) and immune cells (P = .013) were more frequent in NF2mut as compared to NF2wt group. Among histologic subtypes of RCC, cdRCC, sRCC, pRCC, and uRCC are enriched in NF2 GA. Co-occurrent GA in CDKN2A/B, SETD2, and BAP1 may represent potential therapeutic targets. Higher level of PD-L1 expression in NF2mut cohort suggests that these tumors might be sensitive to immune checkpoint inhibitor therapies.
Identifiants
pubmed: 36917021
pii: 7077239
doi: 10.1093/oncolo/oyad040
pmc: PMC10322144
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e508-e519Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Cancer Discov. 2016 Nov;6(11):1258-1266
pubmed: 27604489
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancer Res. 2019 Aug 15;79(16):4113-4123
pubmed: 31151962
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Sci Rep. 2020 Jan 20;10(1):701
pubmed: 31959902
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Clin Cancer Res. 2013 Mar 1;19(5):1180-9
pubmed: 23406776
Curr Opin Neurol. 2018 Dec;31(6):740-746
pubmed: 30379704
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32271879
Eur Urol. 2016 Sep;70(3):516-21
pubmed: 26149668
J Mol Diagn. 2019 Nov;21(6):1053-1066
pubmed: 31445211
J Clin Oncol. 2021 Mar 20;39(9):1020-1028
pubmed: 33529051
Eur Urol. 2017 Mar;71(3):405-414
pubmed: 27751729
Nat Commun. 2016 Oct 07;7:13131
pubmed: 27713405
J Clin Oncol. 2022 Jul 20;40(21):2333-2341
pubmed: 35298296
Oncogene. 2016 Feb 4;35(5):537-48
pubmed: 25893302
Sci Transl Med. 2014 May 21;6(237):237ra68
pubmed: 24848258
Urol Oncol. 2020 Oct;38(10):763-773
pubmed: 30478013
Nat Rev Urol. 2020 Dec;17(12):659-678
pubmed: 33051619
Am J Surg Pathol. 2022 May 1;46(5):617-627
pubmed: 35034039
Eur Urol. 2016 Aug;70(2):348-57
pubmed: 26895810
Am J Surg Pathol. 2020 Jul;44(7):901-916
pubmed: 32217839
Ther Adv Urol. 2015 Dec;7(6):365-77
pubmed: 26622321
Clin Cancer Res. 2020 May 1;26(9):2087-2095
pubmed: 31948999
Acta Neuropathol Commun. 2020 Oct 21;8(1):171
pubmed: 33087175
Curr Oncol. 2022 Jan 02;29(1):178-185
pubmed: 35049691
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Oncotarget. 2018 Jan 10;9(12):10723-10733
pubmed: 29535838
Otol Neurotol. 2012 Feb;33(2):244-57
pubmed: 22222570
Nat Rev Neurosci. 2004 Jun;5(6):462-70
pubmed: 15152196
Nat Commun. 2020 Nov 10;11(1):5679
pubmed: 33173047
Mod Pathol. 2020 Feb;33(2):235-244
pubmed: 31231129
Curr Biol. 2006 Apr 4;16(7):702-9
pubmed: 16581517
Eur Urol. 2018 Jan;73(1):71-78
pubmed: 28592388
Anticancer Res. 2013 Jan;33(1):1-11
pubmed: 23267122
Mol Oncol. 2020 Jun;14(6):1207-1223
pubmed: 32083805
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Histopathology. 2022 Oct;81(4):426-438
pubmed: 35596618
Genome Biol. 2014 Aug 27;15(8):433
pubmed: 25159823
Nat Rev Cancer. 2004 May;4(5):381-93
pubmed: 15122209
Orphanet J Rare Dis. 2009 Jun 19;4:16
pubmed: 19545378
Neuro Oncol. 2019 Mar 18;21(4):486-497
pubmed: 30615146
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157